StockNews.AI
TVTX
StockNews.AI
57 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

1. Pomerantz LLP is investigating claims against Travere Therapeutics' executives. 2. Claims involve potential securities fraud and unlawful business practices. 3. On May 15, the FDA planned to discuss an sNDA for FILSPARI. 4. Following the news, TVTX stock dropped by over 20% to $16.80. 5. Investors are encouraged to reach out for participation in the class action.

3m saved
Insight
Article

FAQ

Why Bearish?

The announcement of an investigation typically leads to market distrust, as seen previously. In 2019, similar investigations led to significant stock declines for affected companies due to loss of investor confidence.

How important is it?

The nature of the investigation affects investor perception and market confidence, influencing future stock performance. With direct references to stock price movement, the implications are significant.

Why Short Term?

Immediate market reactions to investigations usually occur within days to weeks. This was evident in the recent 20% drop following the news of FDA discussion and the investigation.

Related Companies

NASDAQ: TVTXNASDAQ: XLRNNASDAQ: RARE
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Travere and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 15, 2025, Travere issued a press release disclosing that the U.S. Food and Drug Administration (“FDA”) “has indicated that it is currently planning to hold an advisory committee meeting to discuss” the Company’s “supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS).”  On this news, Travere’s stock price fell $4.35 per share, or 20.57%, to close at $16.80 per share on May 16, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News